Vendor, Maple Grove, MN, part of Teleflex Incorporated
Vascular Solutions LLC
UEI CMZHMVNAALR1, CAGE 1SG48
2 awards and $1,473,077 obligated between September 5, 2024 and September 29, 2025, 50% under full and open competition, against 1.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $1,473,077 |
How it wins
Awards by competition, set-aside and type.
| Not Competed | 1 |
| Full and Open Competition | 1 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| W81XWH20C0088Definitive Contract, September 5, 2024, Not Competed, 1 offers | Army Med Res Acq ActivityDefense Health Agency | Advanced Development Activities Necessary to Successfully Obtain Commercial Viability of an U.S. Food and Drug Administration (Fda) LicensedNAICS 541715, PSC AN95 | $1,933,144 |
| W81XWH20C0099Definitive Contract, May 27, 2025, Full and Open Competition, 1 offers | Army Med Res Acq ActivityDefense Health Agency | Development of Lyophilized Cryoprecipitate for FAR Forward Military OperationsNAICS 541715, PSC AN92 | -$460,067 |
- Places of performance
- Minnesota
- Product and service codes
- AN95 N – Health R&D ServicesAN92 N – Health R&D Services
- Transactions
- 6 across 2 awards